Novel 5-desmethylene analogs of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid as potential anticancer agents
摘要:
The synthesis and biological activity of novel 5-desmethylene analogues of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF), a potent antitumor agent presently undergoing clinical trials, are described. These compounds are representative of a new series of optically pure analogues of DDATHF.
Novel 5-desmethylene analogs of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid as potential anticancer agents
摘要:
The synthesis and biological activity of novel 5-desmethylene analogues of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF), a potent antitumor agent presently undergoing clinical trials, are described. These compounds are representative of a new series of optically pure analogues of DDATHF.
A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR
申请人:ELI LILLY AND COMPANY
公开号:EP1212325A2
公开(公告)日:2002-06-12
[EN] A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR<br/>[FR] NOUVELLE FORME CRISTALLINE DE DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L- SEL D'ACIDE GLUTAMIQUE ET PROCEDES DE PREPARATION
申请人:LILLY CO ELI
公开号:WO2001014379A2
公开(公告)日:2001-03-01
The invention relates to the field of organic and pharmaceutical chemistry and provides an improved process for preparing the multi-targeted antifolate N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid and crystals thereof.
Novel 5-desmethylene analogs of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid as potential anticancer agents
作者:Edward C. Taylor、Paul Gillespie、Mona Patel
DOI:10.1021/jo00037a047
日期:1992.5
The synthesis and biological activity of novel 5-desmethylene analogues of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF), a potent antitumor agent presently undergoing clinical trials, are described. These compounds are representative of a new series of optically pure analogues of DDATHF.